Weight & Metabolic Health

❍ At a glance

• Waist circumference is more clinically useful than BMI for metabolic risk. Use ethnicity-adjusted thresholds: for Maori and Pacific patients, elevated risk begins at waist circumference ≥90 cm in men and ≥80 cm in women - lower than the standard European thresholds. Standard thresholds underestimate metabolic risk in these populations.
• 5-10% weight loss produces disproportionate metabolic benefit: roughly 30-50% improvement in insulin sensitivity, meaningful blood pressure reduction, and improved lipid profiles. This is clinically achievable and worth framing positively.
• GLP-1 receptor agonists (semaglutide) produce mean weight loss of 12-15% with significant cardiovascular benefit in people with obesity and established CVD. Currently subsidised in NZ for type 2 diabetes only, not weight management alone. This will change - the subsidy landscape is evolving rapidly.
• Language matters clinically. Stigmatising framing is associated with worse outcomes and avoidance of care. Use "weight" not "obese," discuss health impacts rather than appearance, and ask permission before raising the topic.

❍ Beyond BMI: waist circumference and metabolic risk

BMI is a useful population-level epidemiological tool and a poor individual clinical measure. It does not capture fat distribution, muscle mass, or metabolic risk with sufficient precision to guide individual management. Waist circumference is more strongly associated with cardiovascular and metabolic risk and is straightforward to measure.

Thresholds for elevated metabolic risk:

• European men: ≥94 cm
• European women: ≥80 cm
• Maori, Pacific, and Asian men: ≥90 cm (lower threshold reflects higher metabolic risk at equivalent adiposity)
• Maori, Pacific, and Asian women: ≥80 cm

Maori and Pacific peoples are at significantly higher metabolic risk at any given BMI. Standard European thresholds underestimate risk in these populations.² The ethnicity-adjusted waist circumference cut-offs should be applied when assessing cardiometabolic risk in these groups.

❍ Metabolic syndrome and the case for weight loss

Metabolic syndrome - the clustering of central adiposity, hypertension, dyslipidaemia, and impaired glucose metabolism - identifies individuals at substantially elevated cardiovascular and type 2 diabetes risk. Treatment addresses each component, but weight loss is the central intervention: even modest weight loss of 5-10% produces improvements across all metabolic parameters simultaneously.

The response to modest weight loss is disproportionate to the magnitude: a 5% reduction in body weight produces roughly 30-50% improvement in insulin sensitivity, clinically significant blood pressure reduction, and improved lipid profiles.³ Frame this positively for patients - achievable goals produce real metabolic benefit.

❍ Lifestyle intervention: the foundation

Structured dietary change and physical activity remain the foundation of management. Mediterranean-pattern and low-carbohydrate diets both have evidence for metabolic benefit. The combination of dietary change and exercise consistently outperforms either alone. In practice, the most sustainable approach is the one the patient is willing to maintain - a modest improvement that continues is more useful than an intensive programme that is abandoned after three months.

Physical activity: 150 minutes of moderate-intensity aerobic activity per week as a minimum, with resistance training for metabolic benefit. See the physical activity page for detail. Sleep and alcohol also both affect weight and metabolic health substantially - include them in the lifestyle assessment.

❍ Pharmacological treatment and bariatric surgery

GLP-1 receptor agonists have transformed the pharmacological landscape for weight manageme